Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in adverse events at ≥ 12 months compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
QoL · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of people with hospital admissions (from the emergency room) · acute exacerbations of chronic obstructive pulmonary disease
Intravenous magnesium sulfate + standard care may leads to lower proportion of people with hospital admissions (from the emergency… compared with placebo + standard care (low certainty).
1 finding from 1 review
Proportion of people requiring ventilatory support (NIV or assisted ventilation) · acute exacerbations of chronic obstructive pulmonary disease
It is very uncertain whether nebulised magnesium sulfate + standard care changes proportion of people requiring ventilatory support (NIV or assisted… compared with placebo + standard care (very low certainty).
1 finding from 1 review
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Change in oxygen saturation (SaO2) · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Change in dyspnoea score · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
FEV1 · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Proportion of people requiring non‐invasive ventilation · acute exacerbations of chronic obstructive pulmonary disease
It is very uncertain whether intravenous magnesium sulfate + standard care changes proportion of people requiring non‐invasive ventilation compared with placebo + standard care (very low certainty).
1 finding from 1 review
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Length of hospital stay · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Change in oxygen saturation (SaO2) · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Change in dyspnoea score · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Proportion of people with hospital admissions (from the emergency room) · acute exacerbations of chronic obstructive pulmonary disease
It is very uncertain whether nebulised magnesium sulfate + standard care changes proportion of people with hospital admissions (from the emergency… compared with placebo + standard care (very low certainty).
1 finding from 1 review
Incidence of admissions to the ICU · acute exacerbations of chronic obstructive pulmonary disease
It is very uncertain whether nebulised magnesium sulfate + standard care changes proportion of people requiring ICU admission compared with placebo + standard care (very low certainty).
1 finding from 1 review